Lenvatinib/Lenvatinib Capsules: Existing form, mechanism of action and medication guidance

Lenvatinib does exist in capsule form. As an oral drug, lenvatinib capsules are widely used in the treatment of various cancers such as thyroid cancer, renal cell carcinoma, hepatocellular carcinoma, and endometrial cancer. The capsules contain the active ingredient lenvatinib, which exerts its effects by precisely inhibiting angiogenesis and tumor growth.

Specifically, the active ingredient in lenvatinib capsules can selectively inhibit a variety of proteins, such asVEGFR, FGFR, RET, KIT and PDGFR, etc., which are key proteins that cancer cells rely on for growth and reproduction. In this way, lenvatinib blocks signaling pathways that allow cells, both cancerous and normal, to survive and proliferate, particularly those that promote angiogenesis, as blood vessels are an important support for tumor survival and growth. However, it is important to note that since normal cells also contain these proteins, they may also be affected by the treatment.

The use of Lenvatinib capsules must strictly follow the doctor's recommendations and prescriptions. Doctors will develop a personalized dosage and usage plan based on the patient's weight, age, condition, and other relevant factors. Patients must take the capsules at the prescribed time and dosage as directed by their doctor.

Like other drugs, lenvatinib capsules may also cause some adverse reactions, common ones include nausea, vomiting, diarrhea, fatigue and loss of appetite. Therefore, when treating with lenvatinib, doctors will develop a personalized treatment plan based on the patient's specific illness and physical condition, and closely monitor the patient's response to the drug and possible side effects to ensure the safety and effectiveness of the treatment.